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Association Between Val66Met Brain-Derived
Neurotrophic Factor (BDNF) Gene Polymorphism and
Post-Treatment Relapse in Alcohol Dependence
Marcin Wojnar, Kirk J. Brower, Stephen Strobbe, Mark Ilgen, Halina Matsumoto,
Izabela Nowosad, Elzbieta Sliwerska, and Margit Burmeister
Background: The purpose of this study was to examine relationships between genetic markers
of central serotonin (5-HT) and dopamine function, and risk for post-treatment relapse, in a
sample of alcohol-dependent patients.
Methods: The study included 154 patients from addiction treatment programs in Poland, who
met DSM-IV criteria for alcohol dependence. After assessing demographics, severity of alcohol
use, suicidality, impulsivity, depression, hopelessness, and severity of alcohol use at baseline,
patients were followed for approximately 1 year to evaluate treatment outcomes. Genetic poly-
morphisms in several genes (TPH2, SLC6A4, HTR1A, HTR2A, COMT, and BDNF) were tested
as predictors of relapse (defined as any drinking during follow-up) while controlling for baseline
measures.
Results: Of 154 eligible patients, 123 (80%) completed follow-up and 48% (n = 59) of these
individuals relapsed. Patients with the Val allele in the Val66Met BDNF polymorphism and the
Met allele in the Val158Met COMT polymorphism were more likely to relapse. Only the BDNF
Val ⁄Val genotype predicted post-treatment relapse [odds ratio (OR) = 2.62; p = 0.019], and time
to relapse (OR = 2.57; p = 0.002), after adjusting for baseline measures and other significant
genetic markers. When the analysis was restricted to patients with a family history of alcohol
dependence (n = 73), the associations between the BDNF Val ⁄Val genotype and relapse
(OR = 5.76, p = 0.0045) and time to relapse (hazard ratio = 4.93, p = 0.001) were even
stronger.
Conclusions: The Val66Met BDNF gene polymorphism was associated with a higher risk and
earlier occurrence of relapse among patients treated for alcohol dependence. The study suggests a
relationship between genetic markers and treatment outcomes in alcohol dependence. Because a
large number of statistical tests were conducted for this study and the literature on genetics and
relapse is so novel, the results should be considered as hypothesis generating and need to be repli-
cated in independent studies.
Key Words: Alcohol Dependence, Genetic Polymorphism, Brain-Derived Neurotrophic Factor,
Relapse.
A LCOHOL DEPENDENCE IS a cause of majorhealth, social, and economic problems. Within Poland,
it affects about 4 to 9% of the population and causes about
10,000 deaths per year (GUS, 2006). The course of alcohol
dependence is characterized by a persistent vulnerability to
relapse and most treated individuals achieve only short-term
periods of abstinence, regardless of the type of therapy that is
received (Polich et al., 1980; Project MATCH, 1997). An
improved understanding of the underlying basis for relapse
susceptibility in alcohol dependence may help to identify indi-
viduals at risk and facilitate more precise targeting of effective
treatments.
A number of biological markers, including genetic polymor-
phisms, have been associated with a predisposition to develop
alcohol dependence (Covault et al., 2004; Edenberg, 2007;
Edenberg and Foroud, 2006; Edenberg and Kranzler, 2005;
Gscheidel et al., 2000). However, biological predictors of
relapse in alcohol dependence have been systematically investi-
gated only in a few studies. The results from this research indi-
cates that central dopamine (DA) hypofunction (Schmidt
et al., 1996), increased density of striatal dopaminergic D2
receptors (Guardia et al., 2000), and decreased plasma b-
endorphin levels (Marchesi et al., 1997) are potential markers
of increased risk of relapse in alcohol dependence. Other
studies have shown that polysomnographic-recorded sleep
disturbances (Brower et al., 1998; Gann et al., 2001), fast beta
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power or other electroencephalogram abnormalities (Bauer,
2001), and changes in event-related potentials (Glenn et al.,
1993) might be biological markers of risk for relapse. The rela-
tionship between serotonergic activity and vulnerability to
alcohol relapse has received considerably less attention than
the dopaminergic system. In the only study of which we are
aware, George and colleagues (1999) reported a correlation
between higher baseline concentrations of serotonin (5-HT)
metabolites in cerebrospinal fluid and relapse in alcoholic
patients.
The study of genetic vulnerability in predicting relapse in
alcohol-dependent patients is far less common than genetic
studies of initial onset or early risk. Most existing research on
genetic vulnerability and relapse has examined potential asso-
ciations using relatively small samples of alcohol-dependent
patients admitted for alcohol detoxification. In a sample of 89
alcoholic patients followed for 12 months after admission,
for example, Finckh and colleagues (1997) found no evidence
for a significant relationship between the DAD2 receptor gene
polymorphism in exon 8 and incidence of relapse. Also, other
groups (Heinz et al., 1996; Wiesbeck et al., 2003) reported no
evidence that particular D1, D2, or D3 DA receptor gene
variants had any association with treatment outcomes in small
samples of patients (N = 97 and N = 136, respectively) fol-
lowed for 6 or 12 months after inpatient admission. In a recent
study, Pinto and colleagues (2008) reported that the S allele of
the 5-HT transporter (5-HTT)-linked polymorphic region
(5-HTTLPR) may have increased the risk of relapse in 48
alcohol-dependent patients. Also, recently, Bauer and collea-
gues (2007) reported the promising finding in a large sample of
812 subjects treated in ProjectMATCH that theG-allele of the
GABRA2 gene, which codes for a subunit of the c-aminobutyr-
ic acid receptor, was associated with significantly increased
probabilities of both drinking and heavy drinking during and
after treatment. Interestingly, theGABRA2 genotype also pre-
dicted differential treatment outcomes as a function of the
psychotherapy that subjects’ received during treatment.
Given the importance of better understanding relapse, we
previously examined baseline psychosocial predictors of
relapse including psychopathology, impulsivity, depression,
hopelessness, and impulsive suicide attempts (Wojnar et al.,
2008). Here, we extend those findings to explore genetic pre-
disposition to relapse in alcohol dependence that might be
related to 5-HT or DA system dysfunction. Specifically, we
selected 6 genetic polymorphisms that have previously been
associated with suicidality or impulsivity in alcohol-dependent
individuals, in the genes encoding tryptophan hydroxylase
type 2 (TPH2) (Stoltenberg et al., 2006; Zhou et al., 2005), the
5-HTT (Gorwood et al., 2000; Li and He, 2007; Pinto et al.,
2008), 5-HT receptor 2A (HTR2A) (Lemonde et al., 2003;
Serretti et al., 2007) and HTR2B (Preuss et al., 2001;
Vaquero-Lorenzo et al., 2007), catechol-O-methyl transferase
(COMT) (Kia-Keating et al., 2007; Wang et al., 2001), and
brain-derived neurotrophic factor (BDNF) (Dwivedi et al.,
2003; Iga et al., 2007; Matsushita et al., 2004). These 6 vari-
ants were tested for their association with vulnerability to
relapse in a treatment sample of alcohol-dependent patients.
As prior work has not examined the extent to which genetic
factors may interact with a family history of alcohol depen-
dence to predict relapse, we also analyzed the interaction of
family history with genetic polymorphisms that were signifi-
cantly associated with relapse in this study.
MATERIALS AND METHODS
Participants
One hundred and fifty-four patients consecutively admitted to
addiction treatment programs in Warsaw, Poland, who met criteria
for alcohol dependence participated in this prospective naturalistic
study. Recruitment occurred at 4 abstinence-based treatment centers
in Warsaw, Poland, including 2 outpatient and 2 residential alcohol
treatment programs. A more detailed description of the study sample
and the treatment programs has previously been published (Wojnar
et al., 2008).
The majority of participants (N = 120; 77.9%) were recruited
from residential treatment programs. Participants from these 2
settings differed in education level (mean 14.1, SD: 2.7 years for out-
patients vs. mean 11.7, SD: 3.8 years for residential patients,
p = 0.001) and employment status (70.6% vs. 22.5%, respectively;
p < 0.001). The groups did not significantly differ in any other base-
line characteristics. For the purposes of this study the 2 treatment
groups were combined (n = 154).
Diagnoses using criteria from the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) (APA, 2000)
were confirmed by consensus of a multidisciplinary team specializing
in the treatment of addictions that included a psychiatrist and an
addictions therapist. All study participants were European Cauca-
sians. One hundred and twenty-three patients (80%) completed a
standardized follow-up assessment during the 12 months following
baseline, which constituted the sample for this study. Further descrip-
tion of the study sample is provided in Table 1.
Patients with follow-up data (n = 123) were more likely than
those without (n = 31) to be in a stable relationship (87% vs. 71%,
p = 0.04), have higher educational achievement (13.5 vs. 12.0 years;
p = 0.04), and be employed (86.3% vs. 71.6%; p = 0.04). Addition-
ally, those with follow-up data drank less alcohol prior to the base-
line assessment [mean: 183.2 (SD: 115.6) vs. 278.7 (179.5) g daily;
p = 0.013] than those without follow-up data. However, these 2
groups did not differ in any other characteristics. The effect of miss-
ing follow-up data is presented below.
Procedures
After a complete description of the study was provided, including
advance notification of follow-up procedures, written informed con-
sent was obtained from all prospective participants. Both the Bioeth-
ics Committee at the Medical University of Warsaw and the
University of Michigan Medical Institutional Review Board
approved the research protocol and use of data for publication.
Patients then completed standardized assessments at baseline and
approximately 1 year later. The baseline assessment included blood
collection (lavender EDTA vacutainers) and questionnaires for eval-
uating psychopathology, depression, impulsivity, hopelessness, and
alcohol use severity. Patients were followed for an average of approx-
imately 12 months to evaluate treatment outcomes.
Measures
The Mini International Neuropsychiatric Interview (M.I.N.I.)
(Sheehan et al., 1998) was used to assess suicide history. Patients were
classified by the presence or absence of a suicide attempt in their
lifetime. In patients with a past suicide attempt, attempts were further
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categorized as ‘‘impulsive’’ or ‘‘non-impulsive,’’ as described in a pre-
vious paper (Wojnar et al., 2008).
Questions about demographics, family history, substance use,
work functioning, legal problems, and social support were obtained
using the University of Arkansas Substance Abuse Outcomes Module
(SAOM), a self-administered questionnaire (Smith et al., 1996). Sub-
stance use questions included a 17-item severity of dependence scale.
The SAOM has excellent test–retest reliability for the drinking ques-
tions (intraclass correlation coefficient = 0.87) and concurrent valid-
ity with the Time-Line Follow-Back (TLFB) Interview (r = 0.74).
The Brief Symptom Inventory (BSI) (Derogatis and Melisaratos,
1983) was used to assess psychiatric severity. It is a validated, 53-item
self-administered instrument that quantifies symptom distress in the
past 7 days. Its General Severity Index was calculated as a T-score,
which was keyed to healthy nonpatient subjects with separate norms
for men and women.
The Barratt Impulsiveness Scale-11 (Barratt, 1959) was used to
measure general impulsivity. It is a 30-item self-report questionnaire
that has been validated in substance-dependent individuals (Allen
et al., 1998).
Severity of depression symptoms was measured using the Beck
Depression Inventory II (BDI-II) (Beck et al., 1996). It has 21 items
with total scores ranging from 0 (no depression) to 63 (severe depres-
sion). The reliability and validity of the BDI in mental health settings
is well established.
To evaluate quantity and frequency of alcohol use both prior to
(past 3 months) and during the study, the TLFB (Sobell et al., 1979,
1988) was administered at baseline and at follow-up assessment. Two
primary outcomes were derived from TLFB data: (1) relapse to any
drinking (yes ⁄no) and (2) time to relapse to any drinking. Relapse
was defined as any drinking during the follow-up period.
Genotyping
DNA was extracted from 7.5 ml of fresh whole blood using Pure-
gene Kits (Gentra Systems, Minneapolis, MN), and an aliquot of
DNA was mailed in batches to the United States. Analyzed
polymorphisms included: rs1386483 in the TPH2; C102T (rs6313) in
the HTR2A; and 4 functional variants: the 5-HTTLPR (in locus
SLC6A4); C()1019)G (rs6295) in the HTR1A; Val158Met (rs4680)
in the COMT; and Val66Met (rs6265) in the BDNF. 5-HTTLPR was
genotyped by polymerase chain reaction (PCR) followed gel
electrophoresis (Gelernter et al., 1998; Sen et al., 2004). The 5 single-
nucleotide polymorphisms were genotyped using inventoried Taq-
Man assays according to the manufacturer’s conditions and solutions
(Applied Biosystems ABI, Foster City, CA). Assays were run on the
University of Michigan DNA Core facility’s ABI PRIZM 7900HT
sequence analyzer. Genotyping error rate in the lab for the
5-HTTLPR repeat based on 472 samples was less than 1.4%. This
was determined as the discrepancy between 2 different sets of PCR
primers and constitutes the upper bound as the method finally
adopted was the more robust, and so we believe most of the discrep-
ancy comes from the older methodology. For the TPH2 TaqMan
assay, the genotyping error rate was 0 ⁄572 by comparing 2 different
assays. In general, TaqMan assay error rates in our lab are well
below 1%. Genotype frequencies did not deviate significantly from
Hardy–Weinberg equilibrium.
Statistical Analysis
Between-group (relapsed or not) comparisons for genotype or
allele frequency differences were performed using the chi-square test,
or Fisher’s exact test when necessary. Between-group differences for
continuous variables were evaluated using the Student’s t-test or
ANOVA. Continuous data are presented as mean and SD.
Genetic polymorphisms and all baseline measures were analyzed
as predictors of post-treatment relapse. Analyses focused on identify-
ing associations between genetic polymorphisms and both rates of
relapse and times to relapse. We began by examining the bivariate
relationships between all genetic variants and relapse within the
follow-up interval using chi-square analyses. In addition, for those
patients who relapsed we compared the mean time to relapse among
studied genotypes using ANOVAs.
Multivariate analyses examined the associations of genotypes with
risk of relapse, after accounting for other baseline factors. Two sepa-
rate multivariate analyses were performed: a multiple logistic regres-
sion analysis predicting relapse and a Cox proportional hazards
regression analysis to predict time to relapse. Finally, Kaplan–Meier
survival analyses were performed to test the relationships of genetic
polymorphisms with probability of time to relapse.
RESULTS
Of 123 patients who completed the study, 73 (59%)
reported a family history of alcohol dependence. During the
Table 1. Baseline Sociodemographic and Clinical Characteristics of Study Participants Who Remained Relapsed or Abstinent at 1-Year Follow-Up
Characteristics Relapsed (n = 59) Abstinent (n = 64) p*
Age (years); mean (SD) 44.15 (10.06) 44.39 (8.90) 0.890
Gender (males); N (%) 45 (76.3) 45 (70.3) 0.456
Married; N (%) 23 (39.0) 29 (45.3) 0.478
Family history of suicide; N (%) 10 (16.9) 10 (15.6) 0.842
Family history of alcohol dependence; N (%) 33 (55.9) 40 (62.5) 0.459
History of other substance use (past 1 month); N (%) 10 (16.9) 8 (12.5) 0.486
Drinking days in past 3 months; median (IQR) 15 (2–49) 4 (0–35.75) 0.032
Number of standard drinks per day; median (IQR) 16.9 (10.8–21.5) 17.4 (14.5–21) 0.378
Severity of psychopathology (GSI; T-score); mean (SD) 50.55 (11.91) 48.98 (12.38) 0.474
Severity of depression (BDI-II); mean (SD) 21.07 (11.93) 18.42 (11.69) 0.219
Impulsiveness (BIS-11); mean (SD) 72.13 (9.87) 70.85 (10.76) 0.497
Prior suicide attempt; N (%) 29 (49.2) 24 (37.5) 0.192
Impulsive suicide attempt; N (%) 20 (33.9) 10 (15.6) 0.018
Addiction treatment during follow-up (hours); median (IQR) 29 (0–106) 48 (16–133) 0.136
Anonymous Alcoholics attendance during follow-up
(number of meetings); median (IQR)
11 (0–45) 24 (4.5–44.5) 0.315
*Chi-square, t-test, or Mann–Whitney test were performed where appropriate. Significant tests are bolded. IQR, interquartile range;
GSI, General Severity Index derived from Brief Symptom Inventory; BDI-II, Beck Depression Inventory version 2; BHS, Beck Hopelessness
Scale; BIS-11, Barratt Impulsiveness Scale.
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1-year follow-up interval, relapse to alcohol use occurred in
59 (48%) patients, 48 of these returned to heavy drinking
(defined as more than 4 drinks a day for more than 4 consecu-
tive days), whereas 11 had just a brief lapse (drinking of a les-
ser amount or a shorter duration than heavy drinking).
Among those who used any alcohol during the study, time to
relapse was on average 218 (SD = 133) days. There were no
significant differences in relapse rates or time to relapse in
patients with (56%; 208 days) or without (44%; 216 days) a
family history of alcohol dependence (p = 0.459; p = 0.645,
respectively).
The genotype and allele frequencies for all analyzed genetic
polymorphisms [BDNF Val66Met, COMT Val158Met,
HTR1A C()1019)G, HTR2A C102T, 5-HTTLPR, and
TPH2 rs1386483] in alcohol-dependent patients who relapsed
and those who remained abstinent, post-treatment relapse
rates for examined genotypes, and times to relapse are pre-
sented in Table 2. Individuals with the Val allele of the BDNF
Val66Met polymorphism and the Met allele of the COMT
Val158Met polymorphism were more likely to relapse than
patients without these respective alleles. The highest relapse
rates were observed in patients with the COMT Val ⁄Met
genotype and the BDNF Val ⁄Val genotype (Table 2). Signifi-
cantly shorter times to relapse were noted in individuals with
the BDNF Val ⁄Val genotype than in the other BDNF geno-
types or other gene variants. Survival analysis also showed
significant differences for BDNF Val66Met genotypes, indi-
cating that the Val ⁄Val genotype was associated with highest
risk for early relapse (log rank test: 7.68, p = 0.024; Fig. 1).
The COMT polymorphism was not associated with early
relapse. For all other genetic markers, neither the genotypic
nor allelic frequencies were significantly different when
comparing patients who relapsed to those who remained
abstinent.
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BDNF Val66Met rs6265 (n = 119)* F = 5.386; p = 0.006
Genotypes Val ⁄ Val 66 (55.5) 27 (45.0) 39 (66.1) 5.594 59.1 178 (135)
Val ⁄ Met 42 (35.3) 25 (41.7) 17 (28.8) p = 0.061 41.9 256 (122)
Met ⁄ Met 11 (9.2) 8 (13.3) 3 (5.1) 27.3 260 (99)
Allele Val 174 (0.73) 79 (0.66) 95 (0.81) 6.52 54.6
Met 64 (0.27) 41 (0.34) 23 (0.19) p = 0.017 35.9
COMT Val158Met rs4680 (n = 115)* F = 1.113; p = 0.332
Genotypes Val ⁄ Val 30 (26.1) 21 (37.5) 9 (15.3) 7.864 30.0 243 (149)
Val ⁄ Met 50 (43.5) 19 (33.9) 31 (52.5) p = 0.020 62.0 202 (127)
Met ⁄ Met 35 (30.4) 16 (28.6) 19 (32.2) 54.3 229 (124)
Allele Val 110 (0.48) 61 (0.55) 49 (0.41) 3.86 44.5
Met 120 (0.52) 51 (0.45) 69 (0.59) p = 0.049 57.5
HTR1A C()1019)G rs6295 (n = 113)* F = 1.307; p = 0.275
Genotypes CC 36 (31.9) 20 (33.9) 16 (29.6) 0.913 44.4 227 (127)
CG 54 (47.8) 29 (49.2) 25 (46.3) p = 0.634 46.3 221 (136)
GG 23 (20.4) 10 (16.9) 13 (24.1) 56.5 174 (123)
Allele C 126 (0.56) 69 (0.58) 57 (0.53) 0.74 45.2
G 100 (0.44) 49 (0.42) 51 (0.47) p = 0.389 51.0
HTR2A C102T rs6313 (n = 113)* F = 0.556; p = 0.575
Genotypes CC 38 (33.6) 17 (28.8) 21 (38.9) 1.893 55.3 200 (125)
CT 62 (54.9) 36 (61.0) 26 (48.1) p = 0.388 41.9 228 (129)
TT 13 (11.5) 6 (10.2) 7 (13.0) 53.8 207 (165)
Allele C 138 (0.61) 70 (0.59) 68 (0.63) 0.31 49.3
T 88 (0.39) 48 (0.41) 40 (0.37) p = 0.575 45.5
SLC6A4 5-HTTLPR (n = 112)* F = 0.041; p = 0.960
Genotypes SS 19 (17.0) 8 (13.8) 11 (20.4) 2.70 57.9 209 (110)
SL 47 (42.0) 22 (37.9) 25 (46.3) p = 0.259 53.2 218 (133)
LL 46 (41.1) 28 (48.3) 18 (33.3) 39.1 212 (143)
Allele S 85 (0.38) 38 (0.33) 47 (0.44) 2.75 55.3
L 139 (0.62) 78 (0.67) 61 (0.56) p = 0.097 43.9
TPH2 rs1386483 (n = 121)* F = 0.787; p = 0.457
Genotypes CC 56 (46.3) 29 (45.3) 27 (47.4) 0.561 48.2 205 (130)
CT 54 (44.6) 28 (43.8) 26 (45.6) p = 0.756 48.1 231 (133)
TT 11 (9.1) 7 (10.9) 4 (7.0) 36.4 248 (143)
Allele C 166 (0.69) 86 (0.67) 80 (0.70) 0.25 48.2
T 76 (0.31) 42 (0.33) 34 (0.30) p = 0.617 44.7
*Sample sizes vary because of difficulties in amplifying some samples; #Pertains to differences in time to relapse. BDNF, brain-derived
neurotrophic factor gene; COMT, catechol-O-methyl transferase gene; HTR1A, serotonin receptor 1A gene; HTR2A, serotonin receptor 2A gene;
5-HTTLPR, serotonin transporter length promoter polymorphism; TPH2, tryptophan hydroxylase type 2 gene. Nominally statistically significant
associations are indicated in bold.
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We constructed logistic regression models to examine
associations between genotypes, which showed significant
associations in bivariate analyses, and post-treatment
relapse, while adjusting for other potential risk factors for
relapse in alcohol dependence. These variables, derived from
our earlier findings (Wojnar et al., 2008), included baseline
demographics (age and gender), severity of pretreatment
alcohol use, severity of psychopathology, impulsivity,
depression, and impulsive suicide attempts. The BDNF
Val ⁄Val genotype significantly predicted relapse [odds ratio
(OR) = 2.62; 95% confidence interval (CI) = 1.18 to 5.85;
p = 0.019] and time to relapse [hazard ratio (HR) = 2.57;
95% CI = 1.30 to 4.69; p = 0.002], while controlling for
the COMT Val ⁄Met genotype and other baseline measures
(Tables 3 and 4). We reran this analysis without the COMT
Val ⁄Met genotype in the model and the results remained
the same.
An additional set of analyses was performed for patients
who endorsed a family history of alcohol dependence
(n = 73). In bivariate analyses, the predictive relationships
between the BDNF Val ⁄Val genotype and relapse
(OR = 4.27; 95% CI = 1.53 to 11.89; p = 0.006), and time
to relapse (HR = 3.43; 95% CI = 1.47 to 8.01; p = 0.004)
were significant in these individuals, but not in patients with-
out a family history. In multivariate analyses (Tables 3 and
4), after controlling for the demographic and clinical measures
previously listed, patients with a family history of alcohol
dependence showed a more pronounced association between
the BDNF Val ⁄Val genotype and relapse (OR = 5.76,
p = 0.005) as well as time to relapse (HR = 4.93,
p = 0.001), which remained significant after correction for
multiple testing. In addition, survival analysis of time to
relapse in patients with a family history of alcohol dependence
confirmed a significant relationship between the BDNF
Val66Met polymorphism and probability of early relapse (log
rank test: 9.22, p = 0.002). Survival analysis in patients with-
out family history was not significant (log rank test = 0.424,
df = 1, p = 0.515). There was a significant interaction
between the BDNF Val66Met polymorphism and family his-
tory of alcohol dependence in the Cox regression model of
risk of relapse in alcohol-dependent patients (p = 0.026;
Fig. 2.).
Supplementary Analyses
A series of additional analyses were undertaken to examine
the effect of lack of follow-up data on the primary results.
Earlier research has shown that individuals lost to follow-up
are more likely to have relapsed than those with follow-up
information (Bottlender and Soyka, 2005; Mann et al., 2005).
Thus, we reclassified all participants with missing follow-up
data as relapsed and reran the bivariate and multivariate anal-
yses related to the BDNF Val66Met polymorphism. These
Fig. 1. Survival time to first relapse for Val66Met BDNF genotypes in
patients with alcohol dependence (n = 123). Relapse = any drinking in the
follow-up. Survival analysis: Kaplan–Meier log rank statistics = 7.68, df = 1,
p = 0.024.
Table 3. Logistic Regression Analysis for Predictors of Post-Treatment Relapse at 1-Year Follow-Up in Alcohol-Dependent Patients
Risk factors for relapse
All patients (n = 123)
Patients with family history of alcohol
dependence (n = 73)
OR 95% CI p OR 95% CI p
BDNF Val66Val genotype 2.62 1.18–5.85 0.019 5.76 1.64–20.31 0.005
COMT Val158Met genotype 1.30 0.53–3.16 0.570 1.79 0.53–6.13 0.351
Alcohol use at baseline* 1.02 1.00–1.03 0.042 1.02 1.01–1.05 0.033
Impulsive suicide attempts 2.37 0.90–6.20 0.080 2.52 0.55–11.47 0.233
Age 0.99 0.95–1.04 0.696 0.97 0.91–1.04 0.414
Severity of psychopathology (GSI) 0.98 0.93–1.03 0.483 1.00 0.93–1.08 0.991
Gender 1.07 0.96–1.21 0.223 1.09 0.90–1.31 0.374
Impulsiveness (BIS-11) 1.00 0.95–1.05 0.939 0.96 0.90–1.03 0.301
Depression (BDI-II) 1.01 0.95–1.08 0.762 1.03 0.94–1.14 0.503
OR, adjusted odds ratio; 95% CI, 95% confidence interval for the OR; BDNF, brain-derived neurotrophic factor gene; COMT, catechol-
O-methyl transferase gene; GSI, General Severity Index derived from Brief Symptom Inventory; BDI-II, Beck Depression Inventory version 2;
BIS-11, Barratt Impulsiveness Scale. Nagelkerke r2 = 0.197; Nagelkerke r2 = 0.376 (for family history of alcohol dependence). Nominally
statistically significant associations are indicated in bold; *number of drinking days in the 90 days before baseline.
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supplementary analyses now included 154 individuals, 64 of
whom were considered as non-relapsed and 90 of whom were
now classified as relapsed. In the bivariate analysis, the effect
of BDNF Val66 allele on the likelihood of relapse remained
significant (v2 = 4.848; p = 0.028) as well as the effect on
the time to relapse (F = 3.818; p = 0.025). Similarly, in the
multivariate models, the effect of BDNF Val66Val genotype
on relapse and time to relapse was significant when control-
ling for other risk factors (OR = 2.24; 95% CI = 1.02 to
4.96; p = 0.046, and HR = 2.11; 95% CI = 1.12 to 3.97;
p = 0.021, respectively).
DISCUSSION
In this study, the Val66Met BDNF polymorphism pre-
dicted relapse and time to relapse among alcohol-dependent
patients during the first year following treatment. The shortest
times to relapse were found in individuals with the BDNF
Val66Val genotype. This genotype was the strongest signifi-
cant predictor of relapse after controlling for other tested
genetic polymorphisms and known risk factors, namely base-
line severity of alcohol use, depression, impulsivity, and a his-
tory of an impulsive suicide attempt. The relationship was
especially pronounced in individuals with a family history of
alcohol dependence, suggesting that the BDNF Val66Val
genotype interacts with family factors to increase vulnerability
to relapse, including either (1) other inherited genetic poly-
morphisms and ⁄or (2) an influence of family environment.
Regardless of whether the mechanism was genetic or environ-
mental, family history moderated the effects of the BDNF
polymorphism on risk for relapse. Given the preliminary nat-
ure of the literature on genetics and relapse and the number
of tests of significance conducted in this study, the results
should be considered as hypothesis generating. However, it is
important to note, that the relationship between the Val66-
Met genotype and time to relapse was significant (e.g.,
p = 0.001) even after applying standard corrections for mul-
tiple significance tests (correcting for 2 to 3 related phenotypes
and 6 polymorphisms).
Although relapse was more frequent in patients with the
COMT Val158Met genotype, the COMT polymorphism
did not predict relapse in the multivariate models. There
were no significant differences in relapse rates or time to
relapse across the other tested polymorphisms [HTR1A
C()1019)G, HTR2A C102T, and TPH2 rs1386483]. The
lack of significant association between risk for relapse in
alcohol-dependent patients and the S allele of the 5-
HTTLPR polymorphism in this study is inconsistent with
results previously reported in a sample of 48 individuals by
Pinto and colleagues (2008). This may be due to differences
in the study sample, different follow up periods, and ⁄or rel-
ative lack of power in our sample.
This study suggests that the functioning of BDNF may be
particularly important in understanding susceptibility to
relapse. BDNF is a neurotrophin involved in the development
and survival of neurons, and in modulating the activity
of neurotransmitter systems (Lipsky and Marini, 2007;
Russo-Neustadt, 2003), particularly 5-HT and DA, which are
associated both with suicidality and the development of
Table 4. Cox Proportional Hazard Regression Analysis for Predictors of Time to Post-Treatment Relapse During 1-Year Follow-Up in
Alcohol-Dependent Patients
Risk factors for time to relapse
All patients (n = 123)
Patients with family history of alcohol
dependence (n = 73)
HR 95% CI p HR 95% CI p
BDNF Val66Val genotype 2.57 1.29–4.69 0.002 4.93 1.92–12.68 0.001
Impulsive suicide attempts 1.97 1.07–3.63 0.029 2.00 0.84–4.78 0.119
Alcohol use at baseline* 1.01 0.99–1.02 0.124 1.02 1.01–1.03 0.015
Age 0.99 0.96–1.03 0.829 0.96 0.91–1.01 0.093
Impulsiveness (BIS-11) 1.01 0.98–1.05 0.536 0.99 0.95–1.04 0.946
Gender 1.06 0.53–2.10 0.877 1.04 0.94–1.16 0.430
Severity of psychopathology (GSI) 0.99 0.97–1.03 0.631 1.01 0.96–1.06 0.634
Depression (BDI-II) 1.02 0.97–1.06 0.482 1.02 0.97–1.08 0.383
HR, adjusted hazard ratio; 95% CI, 95% confidence interval for the hazard ratio; BDNF, brain-derived neurotrophic factor gene; GSI, General
Severity Index derived from Brief Symptom Inventory; BDI-II, Beck Depression Inventory version 2; BIS-11, Barratt Impulsiveness Scale.
Nominally statistically significant associations are indicated in bold; *number of drinking days in the 90 days before baseline.
Fig. 2. Interaction between BDNF Val66Met polymorphism and family
history of alcohol dependence in relationship to the risk of relapse in alcohol-
dependent patients (p = 0.026).
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addictions. Some studies have shown that BDNF may play a
role in the pathogenesis of depression, anxiety, and suicidal
behavior (Duman, 2002; Dwivedi et al., 2003; Hashimoto
et al., 2004; Karege et al., 2005; Kim et al., 2007; Levinson,
2006; Nestler et al., 2002; Perroud et al., 2008; Shelton, 2007).
More recent reports indicate that BDNF, among other neuro-
trophic factors, may be directly involved in the pathogenesis
and development of alcohol dependence (Davis, 2008; Janak
et al., 2006; Joe et al., 2007; Yoon et al., 2006). Uhl and
colleagues (2001) identified the BDNF gene locus as linked to
vulnerability to nicotine or alcohol use.
Although BDNF has been associated with a number of
psychiatric disorders, the differential impact of the BDNF
Val66Met polymorphism in psychiatric disorders is less clear.
Even though substitution of Val66 by Met in the propeptide
of the protein due to a common polymorphism does not
affect the sequence of mature BDNF, the Met allele fails to
localize the protein to synapses in vitro (Egan et al., 2003),
and leads to decreased distribution of BDNF to neuronal
dendrites and reduced activity-dependent secretion (Chen
et al., 2004, 2006). Individuals with the Met allele had smaller
hippocampal volumes (Bueller et al., 2006; Pezawas et al.,
2004) and worse performance on hippocampus-dependent
memory tasks (Egan et al., 2003). Therefore, the Met allele,
responsible for reduced BDNF availability, is considered by
many researchers as a risk factor for psychopathology includ-
ing increased neuroticism, anxiety, depression, and suicide
(Enoch et al., 2008; Hashimoto et al., 2004; Hwang et al.,
2006; Iga et al., 2007). Indeed, a knock-in mouse model
showed decreased hippocampal volume and increased anxiety
(Chen et al., 2006).
However, many other studies suggest that the BDNF Val66
is the susceptibility allele, associated with anxiety and mood
disorders. Sen and colleagues (2003) showed that the Val66
allele was associated with higher neuroticism scores, and many
studies have found a genetic association between the BDNF
Val66 allele and susceptibility to major depression (Frodl
et al., 2007; Jiang et al., 2005; Pezawas et al., 2008; Schumach-
er et al., 2005), bipolar disorder (Lohoff et al., 2005; Neves-
Pereira et al., 2002; Sklar et al., 2002), and substance use disor-
ders (Cheng et al., 2005; Graham et al., 2007; Gratacos et al.,
2007; Lu et al., 2004). Perroud and colleagues (2008) reported
that the Val ⁄Val genotype increased the rate of violent suicide
attempts among adult victims of childhood sexual abuse. As
expected from a complex trait, many studies have not con-
firmed an association between the BDNF Val66Met and neu-
roticism, major depression, bipolar disorder, or substance
abuse.
Thus far, little research has studied possible links between
the BDNF Val66Met polymorphism and alcohol dependence,
and most were either negative (Tsai et al., 2005; Zhang et al.,
2006) or showed just a trend (Liu et al., 2005). Cheng and col-
leagues (2005) found that the Val66 allele was associated with
dependence onmethamphetamine and heroin, andMatsushita
and colleagues (2004) found that the 66Met allele predicted a
greater severity of alcohol dependence (early onset of the
disorder, history of delirium tremens, and violent behavior).
In this study, we found an association between the BDNF Val
allele and an increased risk for poor treatment outcomes—
i.e., relapse to any alcohol use and shorter time to relapse.
While our result is somewhat at odds with the finding that the
BDNF Met allele was associated with greater severity of alco-
holism (Matsushita et al., 2004), the latter study did not mea-
sure relapse as an outcome variable. The Val allele is essential
for ‘‘normal’’ secretion of BDNF and intercellular activity of
the neurotrophin. It is, therefore, somewhat surprising that
the better functioning genetic variant is associated with
relapse to addiction. On the other hand, animal models of
craving and relapse found that elevated levels of BDNF in
mesolimbic DA areas were associated with an increased likeli-
hood of relapse to cocaine use (Lu et al., 2004). In another
study, experimental infusion of BDNF into the nucleus
accumbens led to reinstatement of cocaine self-administration
in rats (Graham et al., 2007). Therefore, BDNF might be
responsible for the persistence of responsiveness to substance-
related cues after withdrawal in alcohol- or drug-dependent
individuals. Finally, in individuals treated for alcohol
dependence, relapse is a very common outcome. Thus,
the association between the more common variant and relapse
could primarily reflect the frequency of this genotype.
Results of this study support the hypothesis that the BDNF
Val66 allele confers a risk for relapse in alcohol-dependent
individuals. Conversely, the Met66 allele may play a protec-
tive role against recurrent drinking after treatment for alcohol
dependence. Despite lack of direct evidence for this hypothe-
sis, results from other studies (Lohoff et al., 2005; Neves-
Pereira et al., 2002; Perroud et al., 2008; Pezawas et al., 2008;
Sen et al., 2003; Sklar et al., 2002) and a neurotrophic theory
of depression seem to support the suggestion that the more
evolutionarily novel Met allele, while responsible for lower
neuronal secretion and decreased activity of BDNF protein
may, in fact, have a protective function in the central nervous
system. Moreover, by modulating the function of both dopa-
minergic and serotonergic systems, BDNF may further influ-
ence addiction-related neurocircuitry leading to relapse.
There are several limitations to this study. The study sam-
ple was relatively small, which limited the power to detect
other significant associations and may have biased our results.
Patients were recruited from 4 treatment centers in Poland.
Compared with countries such as the United States, ethnic
variation is limited in Poland, and the results may not readily
generalize across other ethnic groups. On the other hand, less
diversity in the study sample carries the advantage of analyz-
ing more homogenous phenotypes and genotypes, thereby
increasing statistical power relative to the small sample size.
Additionally, the study examined relapse after an episode of
alcohol treatment; it is not known if results are applicable to
alcohol-dependent individuals who never come for treatment.
The overall rate of relapse in this study of 48% is somewhat
lower than is typically reported in large observational studies.
However, to the best of our knowledge, no comparable
studies have been conducted on individuals seeking treatment
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for alcohol dependence in Poland. It is possible that the
relatively low rate of relapse in this study is due to the fact
that the rate of relapse was much higher in those participants
without follow-up data. When individuals lost to follow-up
were reclassified as relapsed, the relapse rate increased to
58%. Moreover, supplementary analyses of the relationship
between BDNF polymorphism and relapse, which included
these individuals with missing follow-up data, remained sig-
nificant. Nevertheless, the present findings should be consid-
ered with caution until they are replicated in larger samples of
representative alcohol-dependent populations.
A primary outcome measure, time to relapse to any drink-
ing, was based on a single assessment period of approximately
1 year. Although previous research has demonstrated that
timeline follow-back methods can provide accurate data
across this time frame (Sobell et al., 1986), the use of multiple
assessments of post-treatment drinking might increase the
sensitivity and validity of the measure. Recall bias could occur
and participants may not accurately remember the exact tim-
ing of relapse. However, the general consistency of the find-
ings between the logistic regression (which examined risk of
relapse—no vs. yes) and the survival analyses (examining time
to relapse) makes it unlikely that incorrect recollection of the
exact date of relapse fully accounts for the present findings.
Additionally, there is a chance that some of the patients, par-
ticularly those in outpatient programs, may have maintained
active drinking throughout the study without ever achieving
an initial period of abstinence upon starting treatment; thus,
the term ‘‘relapse’’ may not accurately capture the pattern of
drinking of these patients. However, this possibility is unlikely
because of the length and intensity of monitoring in these pro-
grams. Self-report was not verified by biochemical measures
or independently corroborated. Moreover, it is interesting to
note that only 11 individuals lapsed briefly; the majority
(48 ⁄59) returned to heavy drinking. Although this study
lacked sufficient power to distinguish between those with
more minor lapses and those with more significant relapses,
future research should examine whether specific genotypes
could meaningfully differentiate between these groups.
Because this study did not comprehensively assess potential
mediators, the exact mechanisms that explain the relationship
between BDNF polymorphism and relapse are not known.
Knowledge of mechanisms is important for designing targeted
treatment interventions. Therefore, future research with mul-
tiple assessment points prior to the time of relapse should help
to identify potential mediators through which genetics may
impact vulnerability to relapse.
To our knowledge, this is the first study to report a signifi-
cant association between the Val66 allele of BDNF and
increased risk for both any and earlier relapse in patients
admitted to addiction treatment programs, especially in
patients with a family history of alcohol dependence. Our
results, which need to be replicated, highlight the importance
of identifying genetic factors that may place certain
individuals at increased risk for relapse following alcohol
treatment.
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